{"uid":"cap_a5GI6VLOZszD7tPxP2-RQ","slug":"clinicalintelpulse-disease-landscape-c3433ebd","name":"ClinicalIntelPulse Disease Landscape","description":"Competitive drug pipeline landscape for any disease — full Phase 2/3 trial map, mechanism-of-action coverage, approved drugs, PDUFA calendar, M&A activity, opportunity gaps and investment thesis. Worldwide. For biotech and pharma intelligence agents.","url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/disease-landscape","method":"GET","headers":{},"bodySchema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"depth":{"type":"string"},"condition":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}}}},"responseSchema":{"type":"json","example":{"deal_activity":"Highly active M&A space. AstraZeneca acquired Eccogene NASH program ($185M). Roche/Genentech building liver portfolio. Novo Nordisk GLP-1 dominance creating competitive panic.","query_summary":{"as_of":"2026-06-07","depth":"standard","condition":"NASH (Nonalcoholic Steatohepatitis)"},"approved_drugs":[{"name":"Resmetirom (Rezdiffra)","sponsor":"Madrigal Pharmaceuticals","approved":"2024-03","mechanism":"THR-β agonist","indication":"NASH with moderate-to-advanced fibrosis"}],"pdufa_calendar":[{"drug":"Lanifibranor","sponsor":"Inventiva","mechanism":"Pan-PPAR","pdufa_estimate":"2026-Q1","priority_review":false}],"investment_thesis":"NASH market projected $18-25B by 2030. Resmetirom first approval sets pricing precedent. GLP-1 combination therapy is the likely future standard of care.","opportunity_score":{"max":100,"note":"Validated market with first approval. GLP-1 expansion threatening narrow competitors.","score":78,"rating":"High Value"},"pipeline_overview":{"phase2_count":48,"phase3_count":19,"total_active":67,"approved_drugs":2,"approval_recent_12m":1},"top_phase3_assets":[{"drug":"Semaglutide 2.4mg","nctId":"NCT04858633","sponsor":"Novo Nordisk","mechanism":"GLP-1 RA","completion":"2025-Q4","significance":"Blockbuster potential — NASH + obesity combined label"}],"mechanism_landscape":{"crowded":["FXR agonists (8 Phase 2/3)","ACC inhibitors (6)","FGF21 analogs (5)"],"emerging":["Pan-PPAR agonists","GLP-1/GIP combinations (semaglutide expanding)"],"opportunity_gaps":["Cirrhosis reversal agents","Pediatric NAFLD","Combination sequential therapy protocols"]},"key_readouts_next_18m":["NASH-RESOLVE (semaglutide histology 2025)","MAESTRO-NASH (lanifibranor 2025)","ATLAS trial (aldafermin 2026)"]}},"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.35","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.35/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.35","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.35","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_UQ0MWeDhx9Glmi9BUbSep","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.35","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Returns a comprehensive competitive drug pipeline landscape for a given disease, including Phase 2/3 trial map, mechanism-of-action coverage, approved drugs, PDUFA calendar, M&A activity, opportunity gaps, and investment thesis.","exampleAgentPrompt":"Pull me a full competitive drug pipeline landscape for NASH — I need the Phase 2 and Phase 3 trial map, what mechanisms of action are being targeted, the approved drugs on market, upcoming PDUFA dates, any recent M&A activity, and where the whitespace opportunities are for a new entrant.","exampleUseCases":null,"resultDescription":"Returns a structured competitive intelligence report for the queried disease including: a map of all Phase 2 and Phase 3 trials, mechanism-of-action and molecular target coverage, list of approved drugs, PDUFA calendar for late-stage assets, recent M&A and licensing deal activity, identified opportunity gaps, and a synthesized investment thesis — all on a global basis.","failureModes":["Disease name not recognized or too ambiguous — returns error or empty landscape","Rare or ultra-orphan disease with minimal trial data — sparse results with low coverage warning","Payment failure via x402 — 402 response before data is returned","Rate limiting or quota exceeded — 429 response","Service unavailability — 503 or timeout"],"whenToPreferThis":"Use this endpoint when you need a broad, integrated view of the entire competitive landscape for a disease in a single call — covering trials, approvals, MOAs, PDUFA timing, and M&A all together. Prefer this over individual sibling endpoints (trial deep-dive, MOA landscape, approval probability) when the goal is strategic synthesis, investment screening, or opportunity mapping rather than drilling into a single data dimension.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-16T00:42:03.430Z","isFirstParty":false}